HomeCompareAYLA vs BTI

AYLA vs BTI: Dividend Comparison 2026

AYLA yields 374.60% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AYLA wins by $7105.54M in total portfolio value
10 years
AYLA
AYLA
● Live price
374.60%
Share price
$0.53
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7105.58M
Annual income
$4,658,993,972.92
Full AYLA calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — AYLA vs BTI

📍 AYLA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAYLABTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AYLA + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AYLA pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AYLA
Annual income on $10K today (after 15% tax)
$31,841.17/yr
After 10yr DRIP, annual income (after tax)
$3,960,144,876.98/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, AYLA beats the other by $3,960,142,508.34/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AYLA + BTI for your $10,000?

AYLA: 50%BTI: 50%
100% BTI50/50100% AYLA
Portfolio after 10yr
$3552.81M
Annual income
$2,329,498,379.78/yr
Blended yield
65.57%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

AYLA
Analyst Ratings
6
Buy
2
Hold
1
Sell
Consensus: Buy
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AYLA buys
0
BTI buys
0
No recent congressional trades found for AYLA or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAYLABTI
Forward yield374.60%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$7105.58M$37.7K
Annual income after 10y$4,658,993,972.92$2,786.64
Total dividends collected$6876.29M$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: AYLA vs BTI ($10,000, DRIP)

YearAYLA PortfolioAYLA Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$48,160$37,460.20$11,299$598.92+$36.9KAYLA
2$220,138$168,606.60$12,794$703.91+$207.3KAYLA
3$955,821$720,273.70$14,518$829.07+$941.3KAYLA
4$3,945,504$2,922,775.63$16,513$978.64+$3.93MAYLA
5$15,497,234$11,275,544.08$18,827$1,157.84+$15.48MAYLA
6$57,972,988$41,390,948.05$21,518$1,373.12+$57.95MAYLA
7$206,739,282$144,708,184.88$24,657$1,632.46+$206.71MAYLA
8$703,499,231$482,288,199.06$28,329$1,945.74+$703.47MAYLA
9$2,286,525,626$1,533,781,448.26$32,637$2,325.33+$2286.49MAYLA
10$7,105,576,392$4,658,993,972.92$37,708$2,786.64+$7105.54MAYLA

AYLA vs BTI: Complete Analysis 2026

AYLAStock

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.

Full AYLA Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this AYLA vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AYLA vs SCHDAYLA vs JEPIAYLA vs OAYLA vs KOAYLA vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.